Spatial Covariance of Cholinergic Muscarinic M
Parkinson's disease
SPECT
cholinergic M1/M4 receptors
muscarinic receptors
networks
spatial covariance
Journal
Movement disorders : official journal of the Movement Disorder Society
ISSN: 1531-8257
Titre abrégé: Mov Disord
Pays: United States
ID NLM: 8610688
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
received:
23
09
2020
accepted:
01
03
2021
pubmed:
12
5
2021
medline:
1
9
2021
entrez:
11
5
2021
Statut:
ppublish
Résumé
Parkinson's disease (PD) is associated with cholinergic dysfunction, although the role of M1 and M4 receptors remains unclear. To investigate spatial covariance patterns of cholinergic muscarinic M Some 19 PD and 24 older adult controls underwent A cholinergic M Cholinergic muscarinic M
Sections du résumé
BACKGROUND
Parkinson's disease (PD) is associated with cholinergic dysfunction, although the role of M1 and M4 receptors remains unclear.
OBJECTIVE
To investigate spatial covariance patterns of cholinergic muscarinic M
METHODS
Some 19 PD and 24 older adult controls underwent
RESULTS
A cholinergic M
CONCLUSIONS
Cholinergic muscarinic M
Substances chimiques
Cholinergic Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1879-1888Subventions
Organisme : Department of Health
Pays : United Kingdom
Organisme : Medical Research Council
ID : G9817682
Pays : United Kingdom
Informations de copyright
© 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Références
Pringsheim T, Jette N, Frolkis A, Steeves TD. The prevalence of Parkinson's disease: a systematic review and meta-analysis. Mov Disord 2014;29(13):1583-1590.
Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009;8(5):464-474.
Muller ML, Bohnen NI, Kotagal V, et al. Clinical markers for identifying cholinergic deficits in Parkinson's disease. Mov Disord 2015;30(2):269-273.
Perez-Lloret S, Barrantes FJ. Deficits in cholinergic neurotransmission and their clinical correlates in Parkinson's disease. NPJ Parkinson's Dis 2016;2:16001.
Bohnen NI, Kanel P, Muller M. Molecular imaging of the cholinergic system in Parkinson's disease. Int Rev Neurobiol 2018;141:211-250.
Asahina M, Shinotoh H, Hirayama K, et al. Hypersensitivity of cortical muscarinic receptors in Parkinson's disease demonstrated by PET. Acta Neurol Scand 1995;91(6):437-443.
Asahina M, Suhara T, Shinotoh H, Inoue O, Suzuki K, Hattori T. Brain muscarinic receptors in progressive supranuclear palsy and Parkinson's disease: a positron emission tomographic study. J Neurol Neurosurg Psychiatry 1998;65(2):155-163.
Piggott MA, Owens J, O'Brien J, et al. Muscarinic receptors in basal ganglia in dementia with Lewy bodies, Parkinson's disease and Alzheimer's disease. J Chem Neuroanat 2003;25(3):161-173.
McOmish C, Pavey G, McLean C, Horne M, Dean B, Scarr E. Muscarinic receptor binding changes in postmortem Parkinson's disease. J Neural Transm 2017;124(2):227-236.
McMackin R, Bede P, Pender N, Hardiman O, Nasseroleslami B. Neurophysiological markers of network dysfunction in neurodegenerative diseases. NeuroImage Clin 2019;22:101706.
Gratwicke J, Jahanshahi M, Foltynie T. Parkinson's disease dementia: a neural networks perspective. Brain 2015;138(Pt 6):1454-1476.
Colloby SJ, McKeith IG, Burn DJ, Wyper DJ, O'Brien JT, Taylor JP. Cholinergic and perfusion brain networks in Parkinson disease dementia. Neurology 2016;87(2):178-185.
Asanuma K, Tang C, Ma Y, et al. Network modulation in the treatment of Parkinson's disease. Brain 2006;129(Pt 10):2667-2678.
Eckert T, Van Laere K, Tang C, et al. Quantification of Parkinson's disease-related network expression with ECD SPECT. Eur J Nucl Med Mol Imaging 2007;34(4):496-501.
Moeller JR, Nakamura T, Mentis MJ, et al. Reproducibility of regional metabolic covariance patterns: comparison of four populations. J Nucl Med 1999;40(8):1264-1269.
Huang C, Mattis P, Tang C, Perrine K, Carbon M, Eidelberg D. Metabolic brain networks associated with cognitive function in Parkinson's disease. Neuroimage 2007;34(2):714-723.
Huang C, Tang C, Feigin A, et al. Changes in network activity with the progression of Parkinson's disease. Brain 2007;130(Pt 7):1834-1846.
Gibb WRG, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-752.
Fahn S, Elton RL, Marsden CD, Goldstein M. Unified Parkinson's disease rating scale. In: Stanley Fahn C, Marsden D, eds. Recent Developments in Parkinson's Disease. Vol. II; Florham Park, New Jersey, USA: Macmillan Health Care Information; 1987:153-163.
Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12(3):189-198.
Roth M, Tym E, Mountjoy CQ, et al. CAMDEX a standardised instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia. Br J Psychiatry 1986;149:698-709.
Lawson RA, Yarnall AJ, Duncan GW, et al. Stability of mild cognitive impairment in newly diagnosed Parkinson's disease. J Neurol Neurosurg Psychiatry 2017;88(8):648-652.
Litvan I, Goldman JG, Troster AI, et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord 2012;27(3):349-356.
Nunes PV, Diniz BS, Radanovic M, et al. CAMcog as a screening tool for diagnosis of mild cognitive impairment and dementia in a Brazilian clinical sample of moderate to high education. Int J Geriatr Psychiatry 2008;23(11):1127-1133.
Lee KS, He XS, Jones DW, et al. An improved method for rapid and efficient radioiodination of iodine-123-IQNB. J Nucl Med 1996;37(12):2021-2024.
Pakrasi S, Colloby SJ, Firbank MJ, et al. Muscarinic acetylcholine receptor status in Alzheimer's disease assessed using (R, R) 123I-QNB SPECT. J Neurol 2007;254(7):907-913.
Colloby SJ, Pakrasi S, Firbank MJ, et al. In vivo SPECT imaging of muscarinic acetylcholine receptors using (R,R) 123I-QNB in dementia with Lewy bodies and Parkinson's disease dementia. Neuroimage 2006;33(2):423-429.
Colloby SJ, Firbank MJ, Pakrasi S, et al. A comparison of 99mTc-exametazime and 123I-FP-CIT SPECT imaging in the differential diagnosis of Alzheimer's disease and dementia with Lewy bodies. Int Psychogeriatr 2008;20:1124-1140.
Habeck C, Krakauer JW, Ghez C, et al. A new approach to spatial covariance modeling of functional brain imaging data: ordinal trend analysis. Neural Comput 2005;17(7):1602-1645.
Burnham KP, Anderson DR. Model Selection and Multimodel Inference. New York: Springer Verlang; 2002.
Habeck C, Stern Y. Multivariate data analysis for neuroimaging data: overview and application to Alzheimer's disease. Cell Biochem Biophys 2010;58(2):53-67.
Seeley WW, Crawford RK, Zhou J, Miller BL, Greicius MD. Neurodegenerative diseases target large-scale human brain networks. Neuron 2009;62(1):42-52.
Feigin A, Antonini A, Fukuda M, et al. Tc-99m ethylene cysteinate dimer SPECT in the differential diagnosis of parkinsonism. Mov Disord 2002;17(6):1265-1270.
Firbank MJ, Colloby SJ, Burn DJ, McKeith IG, O'Brien JT. Regional cerebral blood flow in Parkinson's disease with and without dementia. Neuroimage 2003;20(2):1309-1319.
Van Laere K, Santens P, Bosman T, De Reuck J, Mortelmans L, Dierckx R. Statistical parametric mapping of (99m)Tc-ECD SPECT in idiopathic Parkinson's disease and multiple system atrophy with predominant parkinsonian features: correlation with clinical parameters. J Nucl Med 2004;45(6):933-942.
Antonini A, De Notaris R, Benti R, De Gaspari D, Pezzoli G. Perfusion ECD/SPECT in the characterization of cognitive deficits in Parkinson's disease. Neurol Sci 2001;22(1):45-46.
Menon V, Uddin LQ. Saliency, switching, attention and control: a network model of insula function. Brain Struct Funct 2010;214(5-6):655-667.
Seeley WW, Menon V, Schatzberg AF, et al. Dissociable intrinsic connectivity networks for salience processing and executive control. J Neurosci 2007;27(9):2349-2356.
Christopher L, Duff-Canning S, Koshimori Y, et al. Salience network and parahippocampal dopamine dysfunction in memory-impaired Parkinson disease. Ann Neurol 2015;77(2):269-280.
Franciotti R, Delli Pizzi S, Russo M, et al. Somatic symptoms disorders in Parkinson's disease are related to default mode and salience network dysfunction. NeuroImage Clin 2019;23:101932.
Aracil-Bolaños I, Sampedro F, Marín-Lahoz J, et al. A divergent breakdown of neurocognitive networks in Parkinson's disease mild cognitive impairment. Hum Brain Mapp 2019;40(11):3233-3242.
Cosgrove J, Alty JE, Jamieson S. Cognitive impairment in Parkinson's disease. Postgrad Med J 2015;91(1074):212-220.
Weil RS, Winston JS, Leyland L-A, et al. Neural correlates of early cognitive dysfunction in Parkinson's disease. Ann Clin Transl Neurol 2019;6(5):902-912.
Vianney J-M, Miller DA, Spitsbergen JM. Effects of acetylcholine and electrical stimulation on glial cell line-derived neurotrophic factor production in skeletal muscle cells. Brain Res 2014;1588:47-54.
Barrett MJ, Sperling SA, Blair JC, et al. Lower volume, more impairment: reduced cholinergic basal forebrain grey matter density is associated with impaired cognition in Parkinson disease. J Neurol Neurosurg Psychiatry 2019;90(11):1251-1256.
Rochester L, Yarnall AJ, Baker MR, et al. Cholinergic dysfunction contributes to gait disturbance in early Parkinson's disease. Brain 2012;135(Pt 9):2779-2788.
Ray NJ, Bradburn S, Murgatroyd C, et al. In vivo cholinergic basal forebrain atrophy predicts cognitive decline in de novo Parkinson's disease. Brain 2018;141(1):165-176.
Bruck A, Kurki T, Kaasinen V, Vahlberg T, Rinne JO. Hippocampal and prefrontal atrophy in patients with early non-demented Parkinson's disease is related to cognitive impairment. J Neurol Neurosurg Psychiatry 2004;75(10):1467-1469.